Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Stock Price & Analysis
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) — price $58.79 (0.00%), as of the Nov 19, 2026 trading session; market cap $12.2B. Expected results Feb 25, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Recordati Industria Chimica e Farmaceutica S.p.A. · RCDTF · Healthcare · Medical - Pharmaceuticals
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $58.79 | |
| Change on the day | 0.00% | |
| 52-week range | $55.88–$65.44 | |
| Market capitalisation | $12.2B | — |
| Price / earnings (trailing) | 20.73 | |
| Shares traded on the day | 100 | |
| Beta (volatility vs the S&P 500) | 0.58 | |
| Dividends per share (last 12 months) | $1.55 | |
| Dividend yield (last 12 months) | 2.64% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results
- · Earnings results
- · Earnings call · management outlook
- · Earnings results
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Operating expenses maintained well controlled, while SG&A and R&D increased in absolute terms as we continue to invest behind the growth of the business, both remained broadly stable as a percentage of revenue, demonstrating continued operating discipline, though we expect a slight ramp-up in the second half as the additives Isturisa investments in the U.S. reach a full run rate.
Michael McClellan · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF), and what does it report?
Short answer
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. Healthcare / Medical Pharmaceuticals Headquarters: Via Matteo Civitali, 1, Milan, MI, 20148, IT. It employs 4,693 people and is led by Robert Koremans. In Q2 FY2026 it reported revenue of €696M and net income of €116M. The market values it at $12.2B.
What do the latest results show for Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of €696M. Against analyst estimates the company has EPS beat 5 of the last 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $785.06M Nov 10, 2026
- Latest report · revenue estimate
- $761.27M Nov 10, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 10, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 10, 2026 | $785.06M | $761.27M | $0.7600 | Not available |
| Jul 28, 2026 | $796.24M | $778.37M | $0.9100 | Not available |
| May 12, 2026 | $824.27M | $817.74M | $0.8630 | Not available |
| Mar 31, 2026 | $778.70M | $778.42M | $0.8800 | $0.8570 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | €696M | €116M | €0.56 (diluted) |
| Q1 FY2026 | €716M | €154M | €0.74 (diluted) |
| Q4 FY2025 | €662M | €117M | €0.56 (diluted) |
| Q3 FY2025 | €632M | €110M | €0.53 (diluted) |
What are the financial strengths and risks for Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)?
Short answer · as of
The distress and quality screens read Altman Z 3.89 · Piotroski F 7. Trailing ratios: ROE 24.8% · ROA 9.6% · current ratio 1.34 · earnings yield 4.8% · free-cash-flow yield 5.6%.
What should you watch next at Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)?
Short answer · as of
The next earnings report is expected on Feb 25, 2027.
What management is planning
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held RCDTF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported RCDTF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)?
What Investors Ask About Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) — Healthcare
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What makes Recordati more than a rare-disease drug developer?
Recordati already markets medicines across cardiovascular, urology, infection, oncology and other specialty areas while developing and selling rare-disease therapies. The rare-disease portfolio is therefore a growth engine within a broader commercial pharmaceutical business, not the company's sole source of demand.
How do ENJAYMO and Carbaglu fit Recordati's portfolio?
ENJAYMO and Carbaglu target specific rare conditions, complementing Recordati's wider specialty and primary-care franchises. Their demand depends more on identifying eligible patients and specialist treatment than on the broad prescription volumes associated with mature primary-care products.
What is the RCDTF stock price today?
The last price recorded for Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does RCDTF pay a dividend?
Yes. The dividend yield of Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 38 figures on this page — 1 from SEC filings and earnings calls, 29 from Financial Modeling Prep (FMP), 4 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com